Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-02-08
DOI
10.1038/s41467-023-36328-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1–High Expression Using Real-World Data
- (2022) M. Pérol et al. ANNALS OF ONCOLOGY
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer
- (2021) Kathryn C. Arbour et al. CLINICAL CANCER RESEARCH
- CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
- (2021) Elio Adib et al. CLINICAL CANCER RESEARCH
- Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations
- (2021) Alexander P Davis et al. Immunotherapy
- Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.
- (2021) Oladimeji Akinboro et al. JOURNAL OF CLINICAL ONCOLOGY
- Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
- (2021) Xinan Wang et al. JNCI-Journal of the National Cancer Institute
- Structure-based classification predicts drug response in EGFR-mutant NSCLC
- (2021) Jacqulyne P. Robichaux et al. NATURE
- 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
- (2021) Guangchun Han et al. Nature Communications
- Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
- (2021) Marcelo V Negrao et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
- (2021) Ya Chen et al. Frontiers in Oncology
- Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer
- (2021) Kenneth L. Kehl et al. JAMA Network Open
- CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
- (2021) Stanley I. Gutiontov et al. Scientific Reports
- Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
- (2019) K M Heinhuis et al. ANNALS OF ONCOLOGY
- Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
- (2019) Arnaud Jeanson et al. Journal of Thoracic Oncology
- Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer
- (2019) Sandra D. Griffith et al. ADVANCES IN THERAPY
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
- (2019) Yixin Zhou et al. Journal for ImmunoTherapy of Cancer
- The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?
- (2019) Elie Rassy et al. Immunotherapy
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma
- (2018) Jerome Biton et al. CLINICAL CANCER RESEARCH
- Development and Validation of a High-Quality Composite Real-World Mortality Endpoint
- (2018) Melissa D. Curtis et al. HEALTH SERVICES RESEARCH
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
- (2018) Diana Miao et al. NATURE GENETICS
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now